Free Trial

McKesson (MCK) Stock Forecast & Price Target

McKesson logo
$597.31 +12.93 (+2.21%)
Closing price 03:59 PM Eastern
Extended Trading
$597.50 +0.19 (+0.03%)
As of 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
14

Based on 16 Wall Street analysts who have issued ratings for McKesson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 2 have given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for MCK.

Consensus Price Target

$646.14
8.18% Upside
According to the 16 analysts' twelve-month price targets for McKesson, the average price target is $646.14. The highest price target for MCK is $688.00, while the lowest price target for MCK is $579.00. The average price target represents a forecasted upside of 8.18% from the current price of $597.31.
Get the Latest News and Ratings for MCK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for McKesson and its competitors.

Sign Up

MCK Analyst Ratings Over Time

TypeCurrent Forecast
1/24/24 to 1/23/25
1 Month Ago
12/25/23 to 12/24/24
3 Months Ago
10/26/23 to 10/25/24
1 Year Ago
1/24/23 to 1/24/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
12 Buy rating(s)
9 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
4 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$646.14$650.14$610.86$489.31
Forecasted Upside8.18% Upside12.26% Upside20.39% Upside0.89% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

MCK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MCK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

McKesson Stock vs. The Competition

TypeMcKessonMedical CompaniesS&P 500
Consensus Rating Score
2.94
2.82
2.52
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside8.18% Upside12,606.26% Upside11.30% Upside
News Sentiment Rating
Positive News

See Recent MCK News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/10/2025Citigroup
3 of 5 stars
Daniel Grosslight
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$713.00 ➝ $677.00+15.15%
1/6/2025Bank of America
3 of 5 stars
 Lower TargetBuy ➝ Buy$680.00 ➝ $650.00+11.48%
12/17/2024Morgan Stanley
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$612.00 ➝ $642.00+14.35%
12/13/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$535.00 ➝ $641.00+10.71%
12/4/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Valiquette
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$630.00+1.95%
11/7/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Coldwell
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
11/7/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$560.00 ➝ $680.00+23.79%
11/7/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform$531.00 ➝ $688.00+25.25%
10/7/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$665.00 ➝ $630.00+29.78%
9/25/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$623.00 ➝ $579.00+20.99%
8/21/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$656.00 ➝ $661.00+19.54%
8/8/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$596.00 ➝ $616.00+12.78%
6/24/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$570.00 ➝ $670.00+11.10%
5/8/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$563.00 ➝ $652.00+19.74%
5/8/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$620.00 ➝ $630.00+14.00%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
8/11/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$450.00 ➝ $485.00+11.71%
5/9/202358.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:34 PM ET.


Should I Buy McKesson Stock? MCK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, January 22, 2025. Please send any questions or comments about these McKesson pros and cons to contact@marketbeat.com.

McKesson
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in McKesson Co.:

  • McKesson Co. reported a strong earnings per share (EPS) of $7.07 for the latest quarter, exceeding analysts' expectations of $6.88, indicating robust financial performance.
  • The company achieved a revenue of $93.65 billion for the quarter, significantly higher than the anticipated $89.33 billion, showcasing its strong market position and demand for its services.
  • With a year-over-year revenue increase of 21.3%, McKesson Co. demonstrates substantial growth potential, which could attract investors looking for expanding companies.
  • The current stock price is approximately $572.79, reflecting a positive market sentiment and potential for appreciation as analysts maintain a consensus target price of $646.14.
  • McKesson Co. has a low dividend payout ratio of 14.71%, suggesting that the company retains a significant portion of its earnings for reinvestment, which could lead to future growth and increased shareholder value.

McKesson
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in McKesson Co. for these reasons:

  • The company has a negative return on equity of 207.50%, which may raise concerns about its efficiency in generating profits from shareholders' equity.
  • Despite the revenue growth, McKesson Co. has a net margin of only 0.77%, indicating that its profitability is relatively low compared to its revenue, which could be a red flag for potential investors.
  • Recent insider selling activity, such as the sale of 579 shares by an executive vice president, may signal a lack of confidence in the company's short-term prospects.
  • Analysts have mixed ratings on the stock, with two holding a "neutral" rating, which may suggest uncertainty about the company's future performance.
  • The healthcare sector can be highly volatile and subject to regulatory changes, which could impact McKesson Co.'s operations and profitability.

MCK Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for McKesson is $646.14, with a high forecast of $688.00 and a low forecast of $579.00.

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last year. There are currently 2 hold ratings, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MCK shares.

According to analysts, McKesson's stock has a predicted upside of 8.18% based on their 12-month stock forecasts.

Over the previous 90 days, McKesson's stock had 2 upgrades by analysts.

McKesson has been rated by research analysts at Baird R W, Bank of America, Citigroup, Evercore ISI, Mizuho, Morgan Stanley, Robert W. Baird, and Wells Fargo & Company in the past 90 days.

Analysts like McKesson more than other "medical" companies. The consensus rating score for McKesson is 2.94 while the average consensus rating score for "medical" companies is 2.82. Learn more on how MCK compares to other companies.


This page (NYSE:MCK) was last updated on 1/23/2025 by MarketBeat.com Staff
From Our Partners